Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-κB inhibition.
about
Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic ApproachesPotential anti-cancer activities and mechanisms of costunolide and dehydrocostuslactoneDetyrosinated microtubules modulate mechanotransduction in heart and skeletal muscleROCK inhibition promotes microtentacles that enhance reattachment of breast cancer cellsMechanisms of Chromosome Congression during Mitosis.Chlamydia trachomatis remodels stable microtubules to coordinate Golgi stack recruitment to the chlamydial inclusion surface.Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression.Molecular Pathways: New Signaling Considerations When Targeting Cytoskeletal Balance to Reduce Tumor Growth.Emerging Anti-Mitotic Activities and Other Bioactivities of Sesquiterpene Compounds upon Human Cells.Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.Discovery of a non-stereoselective cytochrome P450 catalyzing either 8α- or 8β-hydroxylation of germacrene A acid from the Chinese medicinal plant, Inula hupehensis.N-[11CH3]Dimethylaminoparthenolide (DMAPT) uptake into orthotopic 9LSF glioblastoma tumors in the rat.The natural sesquiterpene lactones arglabin, grosheimin, agracin, parthenolide, and estafiatin inhibit T cell receptor (TCR) activation.Extracting microtentacle dynamics of tumor cells in a non-adherent environment.
P2860
Q26752576-25753E18-A927-4B07-9594-9129BFDA2DB7Q26996069-8E96A783-078C-4F17-9587-FF86382F35AAQ27321531-F0CD1985-F151-40EC-90B6-10548DBF8D17Q30408828-E7E2AE4E-C530-4FBA-BE43-C3E35BD3FEC1Q37728193-19CB2BE4-E1A8-4152-8EA8-7C44C084A167Q37843307-1F1F7B47-09AE-41D3-9641-5CD8C8B22C6DQ38592713-F0467240-2585-4F19-B0AA-38C1984B6A4EQ38606432-045A574E-15FA-45B0-BF45-131321E418D0Q38710983-21A4361C-B1B8-47CB-AC45-E20F9A1E36F6Q39048777-1668D487-DF0F-4F51-BDCA-E83442DE132DQ46271876-49B51FE0-6E0E-497D-8291-B64FD76635D7Q47144695-482CF3B5-4E41-4300-B759-1FB11EC0662EQ47319193-E983B801-70FC-4B94-8DAB-543800EC2A4BQ47562369-F9285471-A563-4024-8A09-C0C72643E988
P2860
Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-κB inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Parthenolide and costunolide r ...... pendent from NF-κB inhibition.
@en
Parthenolide and costunolide r ...... pendent from NF-κB inhibition.
@nl
type
label
Parthenolide and costunolide r ...... pendent from NF-κB inhibition.
@en
Parthenolide and costunolide r ...... pendent from NF-κB inhibition.
@nl
prefLabel
Parthenolide and costunolide r ...... pendent from NF-κB inhibition.
@en
Parthenolide and costunolide r ...... pendent from NF-κB inhibition.
@nl
P2093
P2860
P356
P1476
Parthenolide and costunolide r ...... pendent from NF-κB inhibition.
@en
P2093
Amanda E Boggs
Keyata Thompson
Monica S Charpentier
Rebecca A Whipple
Stuart S Martin
P2860
P2888
P356
10.1186/BCR3477
P577
2013-01-01T00:00:00Z
P5875
P6179
1048814713